-
Access to Health Insurance Key to Disparities in Cancer Outcomes
As outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
by Jon Kelvey
-
April 29: The Week in Cancer News
FDA proposes ban on menthol cigarettes, and proton beam therapy on the rise but with growing racial disparity.
by Thomas Celona
-
April 22: The Week in Cancer News
Study finds a connection between bacteria and fast-growing prostate cancer, and researchers measure underrepresentation of Black patients in clinical trials.
by Kevin McLaughlin
-
T Cells Key to COVID-19 Vaccination Efforts
Experts discuss shortcomings of current COVID-19 vaccines in people with cancer while highlighting possibilities of T-cell activation.
by Thomas Celona
-
April 15: The Week in Cancer News
Trial of ‘practice-changing’ immunotherapy yields positive results for lung cancer patients, and CAR T-cell therapy shows effectiveness in targeting certain solid tumors.
by Thomas Celona
-
Exploring Amino Acids’ Impact on Tumor Growth
Researchers are investigating how to match specific dietary changes with therapy to impede cancer progression.
by Thomas Celona
-
Understanding Stress and Cancer
A symposium at the AACR Annual Meeting explores how social factors contribute to elevated risk of cancer in some populations.
by Eric Fitzsimmons
-
The Impact of the RACE for Children Act
Legislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but trials in people under 18 may take years to generate results.
by Marci A. Landsmann
-
Making Collaboration More Common for Rare Cancers
An AACR Annual Meeting 2022 session highlights the impact of research advocacy partnerships for a variety of cancers.
by Marci A. Landsmann
-
Second DCIS Diagnoses May Not Be Related to Initial Lesion
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
by Eric Fitzsimmons
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore